Research brief · Cognitive
PE-22-28
TREK-1 blocker peptide used in antidepressant and neuroplasticity research.
Class
Spadin analogue (TREK-1 channel blocker)
Half-life
~7 h (systemic, preclinical)
Studied in
Antidepressant, neuroplasticity and post-stroke recovery research.
What it is
PE-22-28 is a truncated spadin analogue that selectively blocks the TREK-1 potassium channel. In rodent research it is studied as a fast-acting antidepressant probe with neuroplasticity and post-stroke recovery endpoints.
Mechanism studied
Selective blockade of the two-pore TREK-1 potassium channel, enhancing serotonergic signalling in research models.
Research notes
- Spadin lineage gives clean TREK-1 selectivity for receptor-pharmacology work.
- Frequently studied alongside selank and semax in mood-pathway panels.
Before sourcing any material
- Confirm a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity).
- Check the stated peptide content per vial, not just the gross vial mass.
- Plan reconstitution volumes first so the vial size matches your protocol.
- Verify what is lawful in your jurisdiction — these are in-vitro research reagents, not medicines.